MedTrace Logo

Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients

NCT01183806 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2012-03-20

No results posted yet for this study

Summary

The purpose of this study is to determine whether a exercise program when combined with rivastigmine (Exelon patch) drug treatment compared with rivastigmine drug treatment alone would improve quality of life, ability to perform activities of daily living (ADL) and cognition in patients with Alzheimer's disease.

Hypothesis:

Ho: Rivastigmine drug treatment combined with exercise is not superior to rivastigmine drug treatment to improve quality of life of Alzheimer's disease patients.

H1: Rivastigmine drug treatment combined with exercise is superior to rivastigmine drug treatment to improve quality of life of Alzheimer's disease patients, with an expectative of 15% of improvement in the quality of life scale measurement

Conditions

  • Alzheimer Disease

Interventions

DRUG

Rivastigmine

All patients start on a 5-cm2 rivastigmine transdermal patch and their dose is progressively increased

OTHER

Exercise training program

Exercise training program

Sponsors & Collaborators

  • Federal University of Bahia

    lead OTHER

Principal Investigators

  • Paula Aguiar · Federal University of Bahia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2012-01-31
Completion
2012-03-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01183806 on ClinicalTrials.gov